摘要
背景与目的:大多数胃癌患者确诊时已处于晚期,并伴有相临脏器、淋巴结的广泛侵袭或远处转移。近年来,多西他赛作为一种新的紫杉类药物已通过大量的临床研究证实其可观的疗效,因此我们旨在对比观察多西他赛联合顺铂、5-FU每周方案与三周方案治疗晚期胃癌临床疗效及毒副反应。方法:80例晚期胃癌被分为两组,每周方案组(A组40例):多西他赛25mg/m2静滴,第1,8,15天,顺铂25mg/m2静滴,第1～3天,5-FU500mg/m2静滴,第1～5天,每4周重复。三周方案组(B组40例):多西他赛75mg/m2静滴,第1天,顺铂25mg/m2静滴,第1～3天,5-FU500mg/m2静滴,第1～5天,每3周重复。治疗2个周期评价疗效,每周期评价毒性。结果:两组共80例,均无化疗相关性死亡,A组总有效率42.4%,B组总有效率45.0%,两组中性粒细胞Ⅲ/Ⅳ度减少分别为32.5%和77.5%;非血液学毒性主要是Ⅲ/Ⅳ度疲劳乏力,两组分别为22.5%和42.5%。结论:多西他赛联合顺铂、5-FU治疗晚期胃癌每周与三周治疗相比,疗效相似,但每周治疗血液学毒性反应与疲劳乏力感明显下降,耐受性好。
Background and purpose： The majority of patients with gastric cancer are in advanced stage with either extensive invasion of tumor into the adjacent organs, lymph nodes or distant metastases when diagnosed. As a new anticancer drug of Taxanes, docetaxel has shown considerable promise in advanced gastric cancer through clinical study in these years. We conducted a clinical trial to compare the response and toxic reaction of weekly and 3-weeks＇ docetaxel/cisplatin/ 5-Fu treatment in advanced gastric cancer. Methods： 80 patients were deviede into two groups. Ggroup A： Docetaxel 25 mg/m2 iv d 1,8, 15, cisplatin 25 mg/m^2 iv d 1-3 , 5-FU 500 mg/m^2 iv d 1-5 q4w. Group B： Docetaxel 75 mg/m^2 iv d 1, cisplatin 25 mg/m^2 iv d 1-3 , 5-FU 500 mg/m^2 iv d 1-5 q3w; The clinical responses were assessed after two cycles. Toxicity was assessed every cycle. Results： There was 1 CR in 40 cases, 16 with PR, 14 with SD in group A; there was 1 CR in 40 cases, 17 with PR, 14 with SD in group B. The overall response rates were 42.4% and 45.0% in group A and B, respectively. Grade Ⅲ/IV neatropenia were 32.5% and 77.5% in group A and B. The major non-hematologic toxicity was weakness. Grade Ⅲ/IV weakness were 22.5% and 42.5% in group A and B. Conclusions： The response rates were similar between groups A and B. The occurrence of hematological toxicity and weakness were lower in weekly treatment group.
出处
《中国癌症杂志》
CAS
CSCD
2008年第1期59-62,共4页
China Oncology
关键词
晚期胃癌
多西他赛
顺铂
5-FU
每周治疗
三周治疗
advanced gastric carcinoma
docetaxel
cisplatin
5-FU
weekly treatment
3-weeks＇ treatment
